Celéri Health Launches PatientFinder™ AI Resulting in Dynamic Patient Matching for Clinical Trials and Care Plan Optimization
January 2025 –
PRESS RELEASE – January 15, 2025. Conshohocken, PA – Celéri Health has released its AI-applied large language model (LLM), PatientFinder™, for use in patient matching for clinical trials and for point-of-care advanced therapy patient eligibility identification for care plan optimization.
Patient recruitment is challenging for clinical trials. Matching patients to a site-offered trial can be a challenging process. The typical process includes analyzing a patient’s medical history, understanding the eligibility criteria of each clinical trial, and ensuring a match that satisfies both patient needs and trial requirements. As such, manually matching patients and clinical trials is often labor-intensive, time-consuming, and prone to human errors. PatientFinder™, an end-to-end framework for high quality patient-to-trial matching leverages a large language model. PatientFinder™ comprises three modules for clinical trials: it first performs large-scale filtering to retrieve candidate trial inclusion and exclusion criteria matching; then predicts criterion-level patient eligibility; and finally generates trial-level eligibility scores. The result is a random list of potential candidates for sites to engage for study participation.
AI and its use of LLMs significantly contribute to enhanced clinical decision support and care optimization by leveraging natural language processing to dig deep into patient populations. They analyze vast healthcare data, interpret electronic health records, and extract valuable insights. PatientFinder™ uses common indications and contraindications for some of the top interventional pain therapies: Spinal Cord Stimulation, Non Pulsed Radiofrequency Facet Denervation, SI Joint Fusion, Targeted Drug Delivery – and Chronic Pain Program Admission. Through a bidirectional connection to a practice or program’s EHR, the PatientFinder™ runs across the active patient database to surface matching patients by therapy or treatment type. Physicians and pain providers can see new advanced therapy candidates by type, view the detailed indication matching results, validate based on the provider’s own decision-making, and then choose to engage patients to offer information regarding the potential match of an unexplored therapy. The matching patients can also be offered additional education on new advanced therapies that may be a match through vendor-sponsored education sessions or dynamic electronic opt-in education campaigns.
Our AI-applied large language models like PatientFinder™ are poised to support our research sponsors and investigators as they seek speed to RWE and our over 250 pain provider network striving to pair patients with their optimal care plan in a fast-paced clinical environment. Equally, our pain network point-of-care users of PainIntel™ (our flagship product offering Real World Outcomes® and NIH-validated PROs) will now have ease of access to AI-driven bundles of potential advanced therapy candidates. Each of these new roads for AI, enhance the Celéri user experience as our pain providers strive to leverage their own data for deeper responder storytelling, research growth and practice optimization.
For Market Availability and Inquiries: Cam Teems, VP Commercial Operations & Data, cam@celerihealth.com
About Celéri Health:
The mission of Celéri Health is to make pain a data driven disease by treating every point-of-care encounter like a clinical study visit with the capture of real-world evidence and data streams (Patient-reported Outcomes, diagnoses, drug history, procedure registry, wearables, and physiologic data). Our Real World Outcomes® platform operationalizes the consensus expert recommendations and offers AI-enabled technology, We hold the largest, most comprehensive real world outcomes dataset in pain, including procedure and device usage, medical history, physiological data, longitudinal PROs and pharmaceutical usage. You can learn more about Celéri Health at www.celerihealth.com.
